[{"_1":2,"_3":-5,"_4":-5},"loaderData",{"_5":6,"_7":8,"_9":10},"actionData","errors","root",{"_104":105,"_106":59},"routes/en-gate",{"_103":59},"en-item",{"_11":12},"item",{"_13":14,"_15":16,"_17":18,"_19":-5,"_20":-5,"_21":-5,"_22":23,"_24":25,"_26":27,"_28":29,"_30":27,"_31":32,"_33":34,"_35":36,"_37":38,"_39":40,"_41":-5,"_40":42,"_43":-5,"_44":-5,"_45":-5,"_46":47,"_48":49,"_50":-5,"_51":52,"_53":54,"_55":56,"_57":38,"_58":59,"_60":-5,"_61":62,"_63":64,"_65":38,"_66":38,"_67":68},"id","p4fpu57uc7urmj76evns8igwh","revision",2,"title","#AACR26","originalTitle","summary","reason","source",{"_13":97,"_79":98,"_99":100,"_101":38,"_102":-5},"links",{"_94":95,"_68":96},"publishedAt","2026-04-20T00:25:21.000Z","discoveredAt","2026-10-22T11:08:32.613Z","timelineAt","category","opinion","tags",[],"score",60,"selected",false,"channel","x","story",{"_87":88,"_89":49,"_90":-5,"_91":-5,"_92":93},"insight","digest","conferenceAbstracts","readingMode","full","author","DrMirallas","language","body",{"_83":-5,"_68":84,"_85":-5,"_86":59},"outline",[],"relatedStories",[],"indexable","markdownAvailable",true,"group","conference",{"_77":78,"_79":80,"_81":-5,"_82":-5},"engagement",{"_69":70,"_71":72,"_73":74,"_75":76},"posterIsAuthor","hasTranslation","bodyLanguage","original","heat",16,"likes",9,"replies",1,"reposts",6,"slug","aacr-2026","name","AACR Annual Meeting 2026","topic","reading","zh","

#AACR26

Risvutatug rezetecan (B7H3-TOPI) + Abebrelimab (PD-1)
Dr. Zhong
ARTEMIS-101 (n=253)
NSCLC (ADK) no AGA
ORR 47.1%
mPFS 14m
14pts >12m
Bone marrow

Promising activity of #ADC and #ICI #NSCLC

@MLJohnsonMD2

@SarahCannonDocs
great

@OncoAlert

","zhKind","complete","authorName","Oriol Mirallas MD","handle","avatarUrl","quoted","media",[],"aihot","/items/p4fpu57uc7urmj76evns8igwh","https://x.com/DrMirallas/status/2046022371455410203","aacr26-floor","x.com","kind","x_search","firstParty","iconUrl","ok","changelogVersion","2026-10-23T01:25","enEditionEnabled"]